Component

Acute myocardial infarction in ranelate observational cohorts

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In a five-country study restricted to patients without ranelate contraindications, current ranelate versus current bisphosphonate use had an acute-MI odds ratio of 0.89, 95% CI 0.70–1.12.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Nested case-control studies in healthcare databases.
    limitations
    Selected eligible patients and residual confounding; not proof of cardiovascular safety or a vascular mechanism.
    nutrient_topic
    Strontium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Strontium
    plain_language
    This observational comparison did not detect excess myocardial infarction.
    primary_references
    Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. · 2020 · https://pubmed.ncbi.nlm.nih.gov/32757044/ · DOI 10.1007/s00198-020-05580-0

    Strontium: calcium interactions, cellular mechanisms and mineralization (2026-09-19) · lines 438–444

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Nested case-control studies in healthcare databases. · source_derived_draft · unverified_draft

    ## strontium-cardiovascular-null-ami This observational comparison did not detect excess myocardial infarction. In a five-country study restricted to patients without ranelate contraindications, current ranelate versus current bisphosphonate use had an acute-MI odds ratio of 0.89, 95% CI 0.70–1.12. Model: Nested case-control studies in healthcare databases. Limitations: Selected eligible patients and residual confounding; not proof of cardiovascular safety or a vascular mechanism. Evidence access: Primary abstract Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. · 2020 · https://pubmed.ncbi.nlm.nih.gov/32757044/ · DOI 10.1007/s00198-020-05580-0
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards